In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera (dimethyl fumarate) should remain invalid because the matter had already been resolved by another court.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
8 April 2026 The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.
7 April 2026 On World Health Day 2026, despite data trending in the right direction, systemic barriers continue to limit female inventors—and women's health is suffering.
